Univariate analysis showed that the presence of SML during neoadjuvant therapy, tumor diameter, mitotic index, baseline albumin, and whether to continue imatinib therapy postoperatively were significantly associated with 3-year survival (Table 3). Here, ALB is linked to neoplasm.